



(86) Date de dépôt PCT/PCT Filing Date: 1999/02/23
(87) Date publication PCT/PCT Publication Date: 1999/08/26
(45) Date de délivrance/Issue Date: 2010/10/19
(85) Entrée phase nationale/National Entry: 2000/08/17
(86) N° demande PCT/PCT Application No.: US 1999/003906
(87) N° publication PCT/PCT Publication No.: 1999/042102
(30) Priorités/Priorities: 1998/02/23 (US60/075,555);
1998/12/16 (US60/112,565)

(51) Cl.Int./Int.Cl. *A61K 31/405* (2006.01)


(72) Inventeurs/Inventors:
PAPPOLLA, MIGUEL A., US;
POEGGELER, BURKHARD, DE;
FRANGIONE, BLAS, US;
GHISO, JORGE, US

(73) Propriétaires/Owners:
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION,
US;
NEW YORK UNIVERSITY, US

(74) Agent: BORDEN LADNER GERVAIS LLP

(54) Titre : UTILISATIONS D'ACIDES INDOLE-3-PROPIONIQUES ET DE SELS OU D'ESTHERS DE CES ACIDES
COMME MEDICAMENTS

(54) Title: INDOLE-3-PROPIONIC ACIDS, SALTS AND ESTERS THEREOF USED AS MEDICAMENTS



(57) Abrégé/Abstract:

The cytotoxic effects of amyloid beta protein on cells are prevented by contacting the cells with an effective amount of an indole-3-propionic acid or a salt or ester thereof. Furthermore, a fibrillogenic disease can be treated in a human subject by administering to

(57) **Abrégé(suite)/Abstract(continued):**

the human subject an amount of an indole-3-propionic acid or a salt or ester thereof effective to prevent or reverse fibrillogenesis. Oxidation in a biological sample can be decreased by contacting the biological sample with an effective amount of an indole-3-propionic acid or a salt or ester thereof. Additionally, diseases or other conditions where free radicals and/or oxidative stress play a role can be treated by administering an effective amount of an indole-3-propionic acid or a salt or ester thereof.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/405	A1	(11) International Publication Number: WO 99/42102 (43) International Publication Date: 26 August 1999 (26.08.99)													
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> (21) International Application Number: PCT/US99/03906 (22) International Filing Date: 23 February 1999 (23.02.99) (30) Priority Data: 60/075,555 23 February 1998 (23.02.98) US 60/112,565 16 December 1998 (16.12.98) US (71) Applicants: SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION [US/US]; P.O. Box U-1060, Mobile, AL 36688 (US). NEW YORK UNIVERSITY [US/US]; 70 Washington Square South, New York, NY 10012 (US). (72) Inventor: PAPPOLLA, Miguel, A.; Apartment 1128, 1500 Hillcrest Road, Mobile, AL 36695 (US). (74) Agent: ROGALSKYJ, Peter; Braman & Rogalskyj, LLP, P.O. Box 352, Canandaigua, NY 14424-0352 (US). </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> </td> </tr> </table>			(21) International Application Number: PCT/US99/03906 (22) International Filing Date: 23 February 1999 (23.02.99) (30) Priority Data: 60/075,555 23 February 1998 (23.02.98) US 60/112,565 16 December 1998 (16.12.98) US (71) Applicants: SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION [US/US]; P.O. Box U-1060, Mobile, AL 36688 (US). NEW YORK UNIVERSITY [US/US]; 70 Washington Square South, New York, NY 10012 (US). (72) Inventor: PAPPOLLA, Miguel, A.; Apartment 1128, 1500 Hillcrest Road, Mobile, AL 36695 (US). (74) Agent: ROGALSKYJ, Peter; Braman & Rogalskyj, LLP, P.O. Box 352, Canandaigua, NY 14424-0352 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>											
(21) International Application Number: PCT/US99/03906 (22) International Filing Date: 23 February 1999 (23.02.99) (30) Priority Data: 60/075,555 23 February 1998 (23.02.98) US 60/112,565 16 December 1998 (16.12.98) US (71) Applicants: SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION [US/US]; P.O. Box U-1060, Mobile, AL 36688 (US). NEW YORK UNIVERSITY [US/US]; 70 Washington Square South, New York, NY 10012 (US). (72) Inventor: PAPPOLLA, Miguel, A.; Apartment 1128, 1500 Hillcrest Road, Mobile, AL 36695 (US). (74) Agent: ROGALSKYJ, Peter; Braman & Rogalskyj, LLP, P.O. Box 352, Canandaigua, NY 14424-0352 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>														
(54) Title: INDOLE-3-PROPIONIC ACIDS, SALTS AND ESTERS THEREOF USED AS MEDICAMENTS															
(57) Abstract The cytotoxic effects of amyloid beta protein on cells are prevented by contacting the cells with an effective amount of an indole-3-propionic acid or a salt or ester thereof. Furthermore, a fibrillogenic disease can be treated in a human subject by administering to the human subject an amount of an indole-3-propionic acid or a salt or ester thereof effective to prevent or reverse fibrillogenesis. Oxidation in a biological sample can be decreased by contacting the biological sample with an effective amount of an indole-3-propionic acid or a salt or ester thereof. Additionally, diseases or other conditions where free radicals and/or oxidative stress play a role can be treated by administering an effective amount of an indole-3-propionic acid or a salt or ester thereof. <table border="1" style="margin: 10px auto; border-collapse: collapse;"> <caption>% CELL VIABILITY</caption> <thead> <tr> <th>AB 25-35 (µM)</th> <th>Treatment</th> <th>% Cell Viability (approx.)</th> </tr> </thead> <tbody> <tr> <td rowspan="2">0</td> <td>NONE</td> <td>100</td> </tr> <tr> <td>3IPA / PBN</td> <td>75</td> </tr> <tr> <td rowspan="2">50</td> <td>NONE</td> <td>100</td> </tr> <tr> <td>3IPA / PBN</td> <td>115</td> </tr> </tbody> </table>			AB 25-35 (µM)	Treatment	% Cell Viability (approx.)	0	NONE	100	3IPA / PBN	75	50	NONE	100	3IPA / PBN	115
AB 25-35 (µM)	Treatment	% Cell Viability (approx.)													
0	NONE	100													
	3IPA / PBN	75													
50	NONE	100													
	3IPA / PBN	115													

-1-

INDOLE-3-PROPIONIC ACIDS, SALTS AND ESTERS THEREOF USED AS MEDICAMENTS

5

10 Throughout this application, various
publications are referenced, many in parenthesis. Full
citations for these publications are provided at the
end of each part of the application.

15

FIELD OF THE INVENTION

20 The present invention relates to a use of
indole-3-propionic acid and, more particularly, to the
use of indole-3-propionic acid to prevent cytotoxic
effects of amyloid beta protein, to treat fibrillogenic
diseases, to decrease oxidation in biological samples,
and to treat diseases or other conditions where free
radicals and/or oxidative stress play a role.

25

BACKGROUND OF THE INVENTION

30 It is estimated that ten percent of persons
older than 65 years of age have mild to severe
dementia. Alzheimer's Disease ("AD") is the most
common cause of chronic dementia with approximately two
million people in the United States having the disease.
Although once considered a condition of middle age, it
is now known that the histopathologic lesions of
35 Alzheimer's Disease (i.e., neuritic amyloid plaques,
neurofibrillary degeneration, and granulovascular
neuronal degeneration) are also found in the brains of
elderly people with dementia. The number of such

- 2 -

lesions correlates with the degree of intellectual deterioration. This high prevalence, combined with the rate of growth of the elderly segment of the population, make dementia (and particularly AD) one of the most important current public health problems.

Deposition of cerebral amyloid is a primary neuropathologic marker of Alzheimer's Disease. The amyloid is composed of a 40-42 amino acid peptide called the amyloid beta protein ("A β ") (Glenner and Wong, 1984). Amyloid deposits in AD are found mainly as components of senile plaques, and in the walls of cerebral and meningeal blood vessels (Robakis and Pangalos, 1994).

Molecular cloning showed that A β comprises a small region of a larger amyloid precursor protein ("APP") (Robakis et al., 1987; Weidemann et al., 1989). Briefly, this is a type I integral membrane glycoprotein having a large extracytoplasmic portion, a smaller intracytoplasmic region, and a single transmembranous domain. APP undergoes extensive post-translational modifications (Pappolla and Robakis, 1995; Robakis and Pangalos, 1994) prior to the secretion of its N-terminal portion (Sambamurti et al., 1992; Robakis and Pangalos, 1994). Physiologic processing of APP involves cleavage within the A β sequence by an unidentified enzyme, alpha-secretase (Anderson et al., 1991). Smaller quantities of APP molecules are cleaved at two other sites that could potentially produce amyloidogenic secreted or membrane bound APP (Robakis and Pangalos, 1994). A β is also produced during normal cellular metabolism (Haass et al., 1992; Shoji et al., 1992).

There is some controversy as to whether amyloid causes AD; however, three main lines of

- 3 -

evidence have strengthened the amyloid hypothesis. The first piece of evidence is provided by the identification of several point mutations within the APP gene. These mutations segregate within a subgroup of patients afflicted with a familial form of the disorder and thus suggest a pathogenetic relationship between the APP gene and AD (Chartier-Harlin et al., 1991; Kennedy et al., 1993). Secondly, amyloid deposition temporally precedes the development of neurofibrillary changes (Pappolla et al., 1996) and this observation is also consistent with a link between amyloid and neuronal degeneration. Finally, it has been shown that A β is toxic to neurons (Yankner et al., 1990; Behl et al., 1992; Behl et al., 1994; Zhang et al., 1994), a finding that also strengthened the hypothesis that the amyloid peptide may contribute to the neuronal pathology in AD.

The finding that A β has neurotoxic properties has provided a possible connection between amyloid accumulation and neurodegeneration. Because of the close association between aging and AD and the similarities in the neuropathology of both conditions, oxidative stress has been proposed to play a role in the pathogenesis of AD lesions.

Several investigators demonstrated that oxygen free-radicals ("OFRs") are related to the cytotoxic properties of A β (Behl, 1992; Behl, 1994; Harris et al., 1995; Butterfield et al., 1994; Goodman and Mattson, 1994). Such findings are important, since markers of oxidative injury are topographically associated with the neuropathologic lesions of AD (Pappolla et al., 1992; Furuta et al., 1995; Smith et al., 1995; Pappolla et al., 1996). Because of these observations, antioxidants have been proposed as

- 4 -

potential therapeutic agents in AD (Mattson, 1994; Hensley et al., 1994; Pappolla et al., 1996).

A need continues for methods of treating AD and other fibrillogenic diseases.

5

SUMMARY OF THE INVENTION

The present invention relates to a method of preventing cytotoxic effects of amyloid beta protein on
10 cells. The method includes contacting the cells with an effective amount of an indole-3-propionic acid or an ester or salt thereof.

The present invention further relates to a method of treating a fibrillogenic disease in a human
15 subject. The method includes administering, to the human subject, an amount of indole-3-propionic acid or an ester or salt thereof effective to inhibit or reverse fibrillogenesis.

The present invention also relates to a
20 method of decreasing oxidation in a biological sample. The method includes contacting the biological sample with an effective amount of a indole-3-propionic acid or a salt or ester thereof.

The present invention still further relates to
25 a method of treating diseases or other conditions where free radicals and/or oxidative stress play a role. The method includes administering, to the human subject, an amount of indole-3-propionic acid or an ester or salt thereof effective to treat such disease or condition.

30

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a bar graph illustrating
viabilities expressed as percentages using SK-N-SH
35 human neuroblastoma cells exposed to either A β (25-35)

- 5 -

alone or in conjunction with IPA or PBN.

Figure 2 is a bar graph illustrating viabilities expressed as percentages using PC12 rat pheochromocytoma cells exposed to either A β (25-35) alone or in conjunction with IPA or PBN.

Figure 3 is a bar graph illustrating viabilities expressed as percentages using SK-N-SH human neuroblastoma cells exposed to either A β (1-42) alone or in conjunction with IPA or PBN.

Figure 4 is a bar graph illustrating the degree of lipid peroxidation (MDA measurement) induced by exposing cells to either amyloid peptide A β (1-42) or DDTC alone or each along with IPA.

Figure 5 is a bar graph showing the antioxidant activity of IPA by preventing cell death of PC12 rat neuroblastoma cells induced by inhibition of superoxide dismutase by DDTC.

Figures 6A and 6B are bar graphs showing the effect of IPA on β sheet formation upon incubation of A β (1-40) for 24 hours (Figure 6A) and 48 hours (Figure 6B).

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the discovery that the natural compound indole-3-propionic acid ("IPA") has a combination of properties which render it particularly useful for preventing the cytotoxic effects of amyloid beta protein on cells, for treating any fibrillogenic disease, and for protecting cells from oxidative damage. Accordingly, the compounds of the present invention are powerful therapeutic agents in Alzheimer's Disease and other fibrillogenic diseases, such as, without limitation, prion-related diseases. It may also be used as a


- 6 -

therapeutic agent for the treatment of other diseases where free radicals and/or oxidative stress plays a role. These conditions include Parkinson's Disease, Lewy body dementia, amyotrophic lateral sclerosis, progressive supranuclear palsy, other forms of amyloidoses, stroke, athrosclerosis, emphysema, and some forms of cancer. Furthermore, data show that IPA also has antifibrillogenic activity.

The subject invention provides a method of preventing cytotoxic effects of amyloid beta protein on cells. The method comprises exposing the cells to an effective amount of an indole-3-propionic acid or a salt or ester thereof.

As used herein, "amyloid beta protein" ("A β ") refers to the 40-42 amino acid peptide that makes up the cerebral amyloid which is the primary neuropathologic marker of Alzheimer's Disease ("AD"), and refers to fragments of the A β capable of causing cytotoxic effects on cells. For example, one such fragment of A β is the fragment made of up amino acid residues 25-35 of A β (see Glenner and Wong 1984 for the full amino acid sequence of A β).

As used herein, indole-3-propionic acids are meant to include compounds having the formula:



where R¹, R², R³, R⁴, R⁵, and R⁶ are independently selected from the group consisting of hydrogen,

- 7 -

substituted alkyl groups, unsubstituted alkyl groups, substituted aryl groups, unsubstituted aryl groups, alkoxy groups, substituted or unsubstituted amino groups, thiol groups, alkylthio groups, arylthio groups, and the like. Preferably, R^5 and R^6 are hydrogen. One example of a suitable indole-3-propionic acid is indole-3-propionic acid, which has the above formula where each of R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 is a hydrogen atom. Preferred substituents are those which do not significantly affect the antioxidant and antifibrillogenic properties of the indole-3-propionic acids, as described in more detail below. Other preferred substituents are those which enhance brain-penetration, such as a covalently bonded lipophilic moiety. These substituents can be present on any atom of the indole nucleus which has an available hydrogen. The mode of attachment of the lipophilic moiety is not critical, and can be effected by a carbon-carbon, carbon-oxygen, carbon-nitrogen, or carbon-sulfur bond. To maximize the lipophilicity of the resulting compound, however, it is preferred that attachment be effected so as to minimize polarity. Consequently, it is preferred that the lipophilic moiety be attached via a carbon-carbon bond. The lipophilic moiety can be a hydrocarbon, such as an alkyl having from 5 to 20 carbons. These alkyls can be unsubstituted, such as hexyl or dodecyl, or substituted, such as with an aryl moiety, as in the case where the substituted alkyl is a benzyl or a phenylethyl group. Alternatively, the lipophilic moiety can be substituted or unsubstituted homocyclic rings, such as phenyl groups or a tolyl groups, homocyclic ring systems, heterocyclic rings, heterocyclic ring systems, or multicyclic lipophilic "cage" moieties, such as adamantane. In particular,

- 8 -

the use of the multicyclic "cage" compounds are particularly advantageous (Tsuzuki, 1991).

Some indole-3-propionic acids can be obtained commercially. Others can be prepared by modifications to conventional procedures for the preparation of indole-3-propionic acid, such as the ones described in Johnson and Crosby, 1969) and in U.S. Patent No. 5,300,506, U.S. Patent No. 5,077,293, and JP 03/127,732.

As indicated above, the present invention can also be carried out using salts of the above-described indole-3-propionic acids. Suitable salts include, for example, pharmaceutically acceptable salts, such as sodium salts, potassium salts, and ammonium salts. Salts of indole-3-propionic acid can be made by conventional methods from the corresponding indole-3-propionic acid by mixing the an aqueous solution or dispersion of the acid with an appropriate base (e.g., sodium, potassium, or ammonium hydroxide, or sodium or potassium carbonate).

In addition, also as indicated above, the present invention can be carried out using esters of the above-described indole-3-propionic acids. Examples of such esters include methyl ester, ethyl ester, propyl ester, benzyl ester, and the like. Indole-3-propionic acid esters bearing a lipophilic ester moiety, such as those described above, can also be used advantageously to increase the brain penetration of the indole-3-propionic acid ester. Indole-3-propionic acid esters can be prepared from their corresponding acids or salts by a variety of methods known to those skilled in the art, such as, for example, by first transforming the acid to the acid chloride and then reacting the acid

- 9 -

chloride with a suitable alcohol. Other suitable methods for making esters are described in Kemp and Vellaccio, 1980.

Preferably, the indole-3-propionic acid, salt, or ester has antioxidative and/or antifibrillogenic properties and/or prevents the cytotoxic effects of A β . Various indole-3-propionic acids, salts, and esters can readily be assayed to ensure that the function of preventing the cytotoxic effects of A β is retained using the methodology disclosed herein, such as assays for cell viability, lipid peroxidation, intracellular Ca²⁺, and oxygen free-radicals. The prevention of other cytotoxic effects of A β on cells can readily be observed microscopically, such as the prevention of membrane blebbing, cell retraction, abnormal distribution of chromatin, and karyorrhexis. Antioxidation and antifibrillogenic effects of the various indole-3-propionic acids can be assayed by conventional methods, such as those described in the Examples of this application.

As indicated above, the cytotoxic or cell killing effects of A β include, for example, decreased cell viability (i.e., cell death), increased lipid peroxidation (an indicator of increased oxygen free-radicals), increased intracellular Ca²⁺ levels, diffuse membrane blebbing, cell retraction, abnormal distribution of chromatin towards the nuclear membrane, and karyorrhexis.

The cytotoxic effects of A β are most readily seen in neuronal cells (including cells of the central and peripheral nervous systems), and occur in human subjects afflicted with fibrillogenic diseases, such as Alzheimer's Disease.

The effective amount of the indole-3-

- 10 -

propionic acid (or salt or ester thereof) for prevention of the cytotoxic effects of A β can be readily determined by conventional methods known in the art, such as establishing dose-response curves, as
5 described below. It will be appreciated that the actual preferred amount of the indole-3-propionic acid (or salt or ester thereof) to be administered according to the present invention will vary according to the particular form of the indole-3-propionic acid (i.e.,
10 whether it is a salt, an ester, or an acid), the particular composition formulated, and the mode of administration. Many factors that may modify the action of the indole-3-propionic acid (or salt or ester thereof) can be taken into account by those skilled in
15 the art; e.g., body weight, sex, diet, time of administration, route of administration, rate of excretion, condition of the subject, drug combinations, and reaction sensitivities and severities.

Administration can be carried out continuously or
20 periodically within the maximum tolerated dose. Optimal administration rates for a given set of conditions can be ascertained by those skilled in the art using conventional dosage administration tests.

The invention further provides a method of
25 treating fibrillogenic diseases in a human subject. The method includes administering an amount of an indole-3-propionic acid or a salt or ester thereof effective to inhibit or reverse fibrillogenesis, i.e., inhibit or reverse fibril formation. As used herein,
30 "fibrillogenic diseases" are meant to include any disease or condition involving the undesirable deposition of fibrils. As non-limiting examples thereof, such diseases or conditions include disorders or diseases resulting from abnormal formation of

- 11 -

amyloid or amyloid-like deposits, such as, but not limited to, prion-related encephalopathies, Alzheimer's dementia or disease ("AD"), and other amyloidosis disorders. Examples of prion-related encephalopathies include Creutzfeldt-Jakob disease ("CJD") and Gerstmann-Straussler-Scheinker disease ("GSS") in humans, scrapie in sheep and goats, and spongiform encephalopathy in cattle.

The present invention further provides a method of treating diseases or other conditions where free radicals and/or oxidative stress play a role. The method includes administering an amount of an indole-3-propionic acid or a salt or ester thereof effective to treat the disease or condition. Diseases or conditions where free radicals and/or oxidative stress play a role include, without limitation, Parkinson's Disease, Lewy body dementia, amyotrophic lateral sclerosis, progressive supranuclear palsy, emphysema, and some forms of cancer.

Since indole-3-propionic acid and salts and esters thereof are effective in treating diseases or other conditions where free radicals and/or oxidative stress play a role as well as preventing cytotoxic effects of amyloid beta protein on cells, these compounds are expected to be particularly useful in treating diseases associated with the amyloid beta protein, such as AD.

For all of the indications of indole-3-propionic acid or a salt or ester thereof, suitable dosage amounts are discussed above, and suitable routes of administration include systemic administration (particularly in cases where the indole-3-propionic acid or a salt or ester thereof employed is one which crosses the blood-brain barrier). Systemic

- 12 -

administration includes parenteral and oral administration, for example, as discussed in further detail below.

5 The indole-3-propionic acid or a salt or ester thereof can be administered alone or in combination with compatible carriers as a composition. Compatible carriers include suitable pharmaceutical carriers or diluents. The diluent or carrier ingredients should be selected so that they do not
10 diminish the therapeutic effects of the indole-3-propionic acid or a salt or ester thereof as used in the present invention.

The compositions may be made up in any suitable form appropriate for the desired use; e.g.,
15 oral, parenteral, or topical administration. Suitable dosage forms for oral use include tablets, dispersible powders, granules, capsules, suspensions, syrups, elixirs, and skin patches. Inert diluents and carriers for tablets include, for example, calcium carbonate,
20 sodium carbonate, lactose, and talc. Tablets may also contain granulating and disintegrating agents such as starch and alginic acid, binding agents such as starch, gelatin, and acacia, and lubricating agents such as magnesium stearate, stearic acid, and talc. Tablets
25 may be uncoated or may be coated by known techniques to delay disintegration and absorption. Inert diluents and carriers which may be used in capsules include, for example, calcium carbonate, calcium phosphate, and kaolin. Suspensions, syrups, and elixirs may contain
30 conventional excipients, for example, methyl cellulose, tragacanth, sodium alginate; wetting agents, such as lecithin and polyoxyethylene stearate; and preservatives, e.g., ethyl-p-hydroxybenzoate.

Dosage forms suitable for parenteral

- 13 -

administration include solutions, suspensions, dispersions, emulsions, and the like. They may also be manufactured in the form of sterile solid compositions which can be dissolved or suspended in sterile injectable medium immediately before use. They may contain suspending or dispersing agents known in the art. Examples of parenteral administration are intraventricular, intracerebral, intramuscular, intravenous, intraperitoneal, rectal, and subcutaneous administration.

The present invention also relates to a method of decreasing oxidation in a biological sample. Examples of the types of oxidations that can be decreased using this method include lipid peroxidation and oxidations that are mediated by oxygen free-radical processes. The biological sample can be, for example, a cell or a group of cells, e.g. a tissue. The biological sample is contacted with an indole-3-propionic acid or a salt or ester thereof, such as the ones described above. Contacting can be carried out using any suitable method. For example, the indole-3-propionic acid or a salt or ester thereof can be delivered to the extracellular environment surrounding the biological sample. Alternatively, the indole-3-propionic acid or a salt or ester thereof can be introduced directly into a cell, for example, by microinjection. The amount of indole-3-propionic acid or a salt or ester thereof effective to decrease oxidative processes can be determined by conventional methods, such as by delivering varying amounts of the indole-3-propionic acid or a salt or ester thereof and monitoring the concentration of the products of oxidation, such as oxygen free-radicals or the products of lipid peroxidation.

- 14 -

The present invention will be better understood with respect to the following non-limitative examples.

5 Example 1

Tests were conducted to determine whether IPA had neuroprotective activity against the Alzheimer's amyloid peptide ("A β "). Widespread cerebral deposition of this 40-43 amino acid peptide causes extensive
10 degeneration and death of neurons in Alzheimer's Disease.

To illustrate the cytoprotective affects of IPA against the cytotoxic effects of A β , cells of the human neuroblastoma cell line SK-N-SH were used. These
15 cells were exposed to 50 μ M A β (25-35), the actively toxic fragment of A β (Yankner et al., 1990) with or without 50 μ M of IPA. As a control, the experiments were repeated without A β . As a positive control, the well-known anti-oxidant, phenyl-N-t-butylnitron
20 ("PBN") was substituted for IPA.

The results are shown in Figure 1 as a bar graph illustrating viabilities expressed as percentages. While A β alone has a pronounced cytotoxic effect on the cells, both IPA and PBN have strong
25 protective activity.

Example 2

The experiment of Example 1 was repeated using PC12 rat pheochromocytoma cells. The results are
30 shown in Figure 2 and are essentially identical to the results depicted in Figure 1.

Example 3

The experiment of Example 1 was repeated

- 15 -

using the A β (1-42) peptide using the SK-N-SH human neuroblastoma cell line. The results are shown in Figure 3 and are consistent with those shown with respect to Example 1.

5

Example 4

In order to investigate the possibility that the cytoprotective properties of IPA are also the result, at least in part, of anti-oxidant activity, the levels of malondialdehyde ("MDA"), a marker of lipid peroxidation, in PC12 cells exposed to A β or to oxidative stress were examined. Oxidative stress was delivered by exposing cells to diethyldithiocarbonate ("DDTC"), an inhibitor of superoxide dismutase and an established model of oxidative injury. The PC12 cells were exposed to either amyloid peptide alone or amyloid peptide along with IPA. In other experiments, the cells were exposed to either DDTC alone or DDTC with IPA. The results are shown in Figure 4. It can be seen that IPA significantly decreases the production of malondialdehyde in treated cells, indicating that IPA has anti-oxidant activity. Figure 4 shows both the neuroprotective and the anti-oxidant activities of IPA.

25

Example 5

To further confirm the observations shown in Example 4, we studied whether IPA was effective in preventing death of cells exposed to oxidative stress (DDTC). PC12 neuroblastoma cells were treated with varying amounts of DDTC, with or without varying amounts of IPA. The results are shown in Figure 5. The anti-oxidant activity of IPA is shown by preventing cell death of neuroblastoma cells induced by inhibition of the superoxide dismutase by DDTC. This is in

30

- 16 -

agreement with the previously presented data that IPA increases the survival of cells exposed to DDTC.

Example 6

5 To determine whether IPA had an effect on A β fibrillogenesis, 150 μ M A β (1-40) was incubated with 300 μ M IPA, sodium salt, dissolved in ultrapure water (i.e., distilled, filtered, and sterilized) at a pH of 7. As a control, the ultrapure water used to dissolve
10 the IPA containing an equivalent amount of sodium chloride was added to 150 μ M A β (1-40) at a pH of 7. In one experiment, each of the solutions (i.e., the solution containing IPA and the control solution) was incubated for 24 hours. In a second experiment, each
15 of the solutions was incubated for 48 hours. At the end of each incubation period, 50 mM glycine-NaOH buffer (pH 9.2) containing 2 μ M thioflavin T was added to each sample (5 μ L) to a final volume of 2 mL. Fluorescence, which is a direct measure of β sheet
20 formation, was measured at an excitation wavelength of 435 nm and an emission wavelength of 485 nm using a Hitachi F-2000 fluorescence spectrometer. The average and standard deviations of the mean of 3 samples per condition were determined, and the results are
25 presented (as bar graphs) in Figure 6A (24 hour incubation) and Figure 6B (48 hour incubation). In both the 24 and 48 hour incubation experiments, the amount of fluorescence is significantly less in the samples containing IPA (labeled A-beta + ipa) relative
30 to control (labeled A-beta). This indicates that less β sheet formation occurred in the samples containing IPA relative to control, which, in turn, indicates that IPA is antifibrillogenic.

- 17 -

Although preferred embodiments have been depicted and described in detail herein, it will be apparent to those skilled in the relevant art that various modifications, additions, substitutions and the like can be made without departing from the spirit of the invention and these are therefore considered to be within the scope of the invention as defined in the claims which follow.

- 18 -

REFERENCES

- Anderson, J.P., et al., *Neurosci Lett* 128:126-129 (1991).
- Behl, C., et al., *Biochem Biophys Res Commun* 186:944-950 (1992).
- Behl, C., et al., *Brain Res* 645:253-264 (1994).
- Behl, C., et al., *Cell* 77:817-827 (1994).
- Burdick, D., et al., *J Biol Chem* 267:546-554 (1992).
- Busciglio, J., et al., *Neurobiol Aging* 13:609-612 (1992).
- Busciglio, J., et al., *J Neurochem* 61(4):1565-1568 (1993).
- Butterfield, D.A., et al., *Biochem Biophys Res Commun* 200:710-715 (1994).
- Chartier-Harlin, M.C., et al., *Nature* 353(6347):844-846 (1991).
- Copani, A., et al., *Molecular Pharmacology* 47(5):890-897 (1995).
- Furuta, A., et al., *Am J Pathol* 146:357-367 (1995).
- Glenner, G.G., and Wong, C.W., *Biochem Biophys Res Commun* 120:885-890 (1984).
- Goodman, Y., and Mattson, M.P., *Exp Neurol* 128:1-12 (1994).
- Haass, C., et al., *Nature* 359:322-324 (1992).
- Harris, M.E., et al., *Experimental Neurol* 131:193-202 (1995).
- Hensley, K., et al., *Proc Natl Acad Sci USA* 91(8):3270-3274 (1994).
- Johnson, H.E., and Crosby, D.G., *J Org Chem*, 25:569ff (1969).
- Kemp, D.S., and Vellaccio, F., eds., Organic Chemistry, Worth Publishers, Inc., pp. 371-377 and 1258 (1980).

- 19 -

- Kennedy, A.M., et al., Brain 116:309-324 (1993).
- Le, W-D., et al., Brain Res 686:49-60 (1995).
- Mark, R.J., et al., J Neurosci 15:6239-6249 (1995).
- Mattson, M.P., Ann N Y Acad Sci 747:50-76 (1994).
- Mattson, M.P., et al., Trends Neurosci 16:409-414 (1993).
- Mattson, M.P., et al., J Neurosci 12:376-389 (1992).
- Pappolla, M.A., et al., Am J Pathol 140:621-628 (1992).
- Pappolla, M. A., and Robakis, N.K., In: Perspectives in behavioural medicine, Alzheimers disease and AIDS. Eds Stein, M., and Baum, M., Academic Press, San Diego, CA, pp. 3-20 (1995).
- Pappolla, M.A., et al., Mol Chem Neuropathol 28:21-34 (1996).
- Pike, C.J., et al., J Neurosci 13:1676-1687 (1993).
- Robakis, N.K., and Pangalos, M.N., Neurobiol Aging 15:S127-129 (1994).
- Robakis, N.K., et al., Proc Natl Acad Sci USA 84:4190-4194 (1987).
- Sambamurti, K., et al., J Neurosci Res 33:319-329 (1992).
- Shoji, M., et al., Science 258:126-129 (1992).
- Smith, M.A., et al., Amer J Pathol 145:42-47 (1994).
- Tsuzuki et al., Biochem Pharmacol, 41:R5-R8 (1991).
- Weidemann, A., et al., Cell 57:115-126 (1989).
- Weiss, J.H., et al., J Neurochem 62(1):372-375 (1994).
- Yankner, D.A., et al., Science 250:279-282 (1990).
- Zhang, Z., et al., Neurosci Lett 177:162-164 (1994).

-20-

CLAIMS:

1. The use of an indole-3-propionic acid or a salt or ester thereof for preventing a cytotoxic effect of amyloid beta protein on cells.
2. The use according to claim 1, wherein said cytotoxic effect is cell death.
3. The use according to claim 1, wherein said cytotoxic effect is increased lipid peroxidation.
4. The use according to claim 1, wherein said cytotoxic effect is increased intracellular Ca^{2+} .
5. The use according to claim 1, wherein said cytotoxic effect is increased oxygen free-radicals.
6. The use according to claim 1, wherein said cells are neuronal cells.
7. The use according to claim 1, wherein said cells are present in a human subject and wherein said use is systemically.
8. The use according to claim 1, wherein said cells are present in a human subject having a fibrillogenic disease.
9. The use of an indole-3-propionic acid, or a salt or ester thereof for treating a fibrillogenic disease in a human subject.
10. The use according to claim 9, wherein said indole-3-propionic acid or a salt or ester thereof is for systemically treating a fibrillogenic disease in a human subject.
11. The use according to claim 9, wherein said fibrillogenic disease is Alzheimer's Diseases.

12. The use according to claim 1, wherein said fibrillogenic disease is a prion-related encephalopathy.
13. The use of an indole-3-propionic acid or a salt or ester thereof for decreasing oxidation in a biological sample.
14. The use according to claim 13, wherein said biological sample is a cell.
15. The use according to claim 13, wherein said decreasing oxidation results in decreasing lipid peroxidation.
16. The use according to claim 13, wherein said decreasing oxidation results in decreasing oxygen free-radicals.
17. The use of an indole-3-propionic acid or a salt or ester thereof for treating diseases or other conditions where free radicals or oxidative stress play a roll.
18. The use according to claim 17, where said disease or condition is selected from the group consisting of Parkinson's Disease, Lewy body dementia, amyotrophic lateral sclerosis, progressive supranuclear palsy, stroke, atherosclerosis, emphysema, and cancer.
19. The use according to claim 18 wherein said disease is selected from the group consisting of Parkinson's Disease, Lewy body dementia, amyotrophic lateral sclerosis, progressive supranuclear palsy, and emphysema.
20. The use according to claim 17, 18 or 19, wherein said indole-3-propionic acid or a salt or ester thereof is for systemically treating a fibrillogenic disease in a human subject.
21. The use of indole-3-propionic acid or a salt or ester thereof in the treatment of diseases associated with the cytotoxic effects of amyloid beta protein.

22. The use of indole-3-propionic acid or a salt or ester thereof in the treatment of fibrillogenic diseases.
23. The use of indole-3-propionic acid or a salt or ester thereof in the treatment of Alzheimer's Disease.
24. The use of an indole-3-propionic acid or a salt or ester thereof in the treatment of prion-related encephalopathy.
25. The use of an indole-3-propionic acid or a salt or ester thereof in the treatment of combinations of Alzheimer's disease and a prion-related encephalopathy.
26. The use of indole-3-propionic acid or a salt or ester thereof in the treatment of Parkinson's Disease.
27. The use of indole-3-propionic acid or a salt or ester thereof in the treatment of Lewy body dementia.
28. The use of indole-3-propionic acid or a salt or ester thereof in the treatment of amyotrophic lateral sclerosis.
29. The use of indole-3-propionic acid or a salt or ester thereof in the treatment of progressive supranuclear palsy.
30. The use of indole-3-propionic acid or a salt or ester thereof in the treatment of stroke.
31. The use of indole-3-propionic acid or a salt or ester thereof in the treatment of atherosclerosis.

-23-

32. The use of indole-3-propionic acid or a salt or ester thereof in the treatment of emphysema.
33. The use of indole-3-propionic acid or a salt or ester thereof in the treatment of cancer.
34. The use of indole-3-propionic acid or a salt or ester thereof in the treatment of any combination of Parkinson's Disease, Lewy body dementia, amyotrophic lateral sclerosis, progressive supranuclear palsy, stroke, atherosclerosis, emphysema and cancer.
35. The use of indole-3-propionic acid or a salt or ester thereof in the treatment for preparation of a medicament.

FIG. 1




FIG. 2




FIG. 3

2 / 4






FIG. 4



3 / 4

FIG. 5



4 / 4

FIG. 6A




FIG. 6B

